{"id":2084,"date":"2020-01-01T07:14:00","date_gmt":"2020-01-01T07:14:00","guid":{"rendered":"https:\/\/stage.hallwang2.smithberlin.com\/?p=2084"},"modified":"2025-02-21T12:54:20","modified_gmt":"2025-02-21T12:54:20","slug":"januar-2020","status":"publish","type":"post","link":"https:\/\/www.hallwang-clinic.com\/de_DE\/januar-2020\/","title":{"rendered":"Januar 2020"},"content":{"rendered":"\n<div class=\"wp-block-group\">\n<h2 class=\"wp-block-heading\">Januar 2020 &#8211; Neuigkeiten f\u00fcr HER2-positive Brustkrebspatienten: Neue Therapie verf\u00fcgbar<\/h2>\n\n\n\n<p>Die FDA hat in einem beschleunigten Verfahren die Therapie \u201eFam-Trastuzumab deruxtecan-nxki (Enhertu; DS-8201)\u201c zur Behandlung von erwachsenen Patienten mit inoperablem oder metastasiertem HER2-positivem Brustkrebs zugelassen.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2-positive-breast-cancer\"><strong>https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2-positive-breast-cancer<\/strong><\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Januar 2020 &#8211; Neuigkeiten f\u00fcr HER2-positive Brustkrebspatienten: Neue Therapie verf\u00fcgbar Die FDA hat in einem beschleunigten Verfahren die Therapie \u201eFam-Trastuzumab deruxtecan-nxki (Enhertu; DS-8201)\u201c zur Behandlung von erwachsenen Patienten mit inoperablem oder metastasiertem HER2-positivem Brustkrebs zugelassen. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2-positive-breast-cancer<\/p>\n","protected":false},"author":3,"featured_media":5440,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_locale":"de_DE","_original_post":"https:\/\/www.hallwang-clinic.com\/?p=2084","_htmlclass":"","_bodyclass":"","footnotes":""},"categories":[7],"tags":[],"class_list":["post-2084","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","de_DE","teaser-view"],"_links":{"self":[{"href":"https:\/\/www.hallwang-clinic.com\/wp-json\/wp\/v2\/posts\/2084","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hallwang-clinic.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hallwang-clinic.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hallwang-clinic.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hallwang-clinic.com\/wp-json\/wp\/v2\/comments?post=2084"}],"version-history":[{"count":4,"href":"https:\/\/www.hallwang-clinic.com\/wp-json\/wp\/v2\/posts\/2084\/revisions"}],"predecessor-version":[{"id":5644,"href":"https:\/\/www.hallwang-clinic.com\/wp-json\/wp\/v2\/posts\/2084\/revisions\/5644"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hallwang-clinic.com\/wp-json\/wp\/v2\/media\/5440"}],"wp:attachment":[{"href":"https:\/\/www.hallwang-clinic.com\/wp-json\/wp\/v2\/media?parent=2084"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hallwang-clinic.com\/wp-json\/wp\/v2\/categories?post=2084"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hallwang-clinic.com\/wp-json\/wp\/v2\/tags?post=2084"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}